0001178913-18-000145.txt : 20180111 0001178913-18-000145.hdr.sgml : 20180111 20180111203834 ACCESSION NUMBER: 0001178913-18-000145 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180111 DATE AS OF CHANGE: 20180111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schuz David CENTRAL INDEX KEY: 0001727761 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 18524565 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 3 1 zk1821017.xml OWNERSHIP DOCUMENT X0206 3 2018-01-01 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727761 Schuz David C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET REHOVOT L3 7670402 ISRAEL 0 1 0 0 VP IP Ordinary Shares 6184 D Options 1.92 2020-02-02 Ordinary Shares 59500 D Options 1.92 2024-03-31 Ordinary Shares 6250 D Options 6.77 2025-01-15 Ordinary Shares 18000 D Options 7.13 2025-11-10 Ordinary Shares 11196 D Options 6.34 2026-03-01 Ordinary Shares 30000 D Options 10.31 2027-01-01 Ordinary Shares 32939 D Restricted Share Units 0.00 Ordinary Shares 2816 D Restricted Share Units 0.00 Ordinary Shares 10980 D The Options vested over a period of four years from February 2, 2010 (20% on such date and 5% every three months thereafter) and ending February 2, 2014 The Options vest over a period of four years from March 31, 2014 (20% on such date and 5% every three months thereafter) and ending March 31, 2018 The Options vest over a period of four years from January 15, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending January 15, 2019 The Options vest over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending November 10, 2019 The Options vest over a period of four years from March 1, 2016 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending March 1, 2020 The Options vest over a period of four years from January 1, 2017 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending January 1, 2021 The Restricted Share Units vest in equal installments every three months over the vesting period beginning October 15, 2017 ending January 15, 2019 The Restricted Share Units vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021 The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit List: Exhibit 24 - Power of Attorney /s/ Ilan Hadar as attorney-in-fact for David Schuz 2018-01-11 EX-24 2 exhibit_24.htm EXHIBIT 24
 
Exhibit 24
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Ilan Hadar, Chief Financial Officer, and Mutya Harsch, General Counsel, of Foamix Pharmaceuticals Ltd. (“Foamix Pharmaceuticals”), or any of them, each acting alone, his or her true and lawful attorney-in-fact to:

(1)
execute for and on behalf of the undersigned a Form 3, Form 4 or Form 5, or any amendment thereto, relating to the securities of Foamix Pharmaceuticals, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2)
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of such Form 3, Form 4 or Form 5, or any amendment thereto, and the timely filing of such form with the United States Securities and Exchange Commission and any other authority; and

(3)
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as such attorney-in-fact might or could do if personally present, hereby ratifying and confirming that such attorney-in-fact shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.  This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by Foamix Pharmaceuticals unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of January 2018.
 
 
By: /s/ David Schuz